Use of ouabain antagonists to inhibit viral infection

US11337988B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter L. Collins · Kensington, US
• Matthias Lingemann · Bethesda, US
• Shirin Munir · Bethesda, US

Key dates

• Filing date: Sep 26, 2019
• Grant date: May 24, 2022
• Expiry date: Apr 8, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.